SEARCH:   Advanced

Blood, 1 May 2004, Vol. 103, No. 9, pp. 3529-3534. Prepublished online as a Blood First Edition Paper on December 30, 2003; DOI 10.1182/blood-2003-06-1850. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-06-1850v1 103/9/3529    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lech-Maranda, E. Articles by Salles, G. Search for Related Content PubMed PubMed Citation Articles by Lech-Maranda, E. Articles by Salles, G. Related Collections Immunobiology Neoplasia Clinical Trials and Observations Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma Ewa Lech-Maranda, Lucile Baseggio, Jacques Bienvenu, Carole Charlot, Françoise Berger, Dominique Rigal, Krzysztof Warzocha, Bertrand Coiffier, and Gilles Salles From the Equipe d'Accueil 3737 Pathologie des Cellules Lymphoïdes, Université Claude Bernard, Lyon, France; Department of Hematology, Medical University of Lodz, Lodz, Poland; Service d'Hématologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France; Laboratoire d'Immunologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France; Service d'Anatomie Pathologique, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France; Etablissement Français du Sang, Lyon, France; and Institute of Hematology and Blood Transfusion, Warsaw, Poland. The aim of the study was to investigate whether interleukin-10 (IL-10) genetic polymorphisms influence this cytokine production as well as the incidence and outcome of diffuse large B-cell lymphoma (DLBCL). The frequency of IL-10-1082G allele was found to be higher in 199 patients with DLBCL as compared with 112 control subjects (0.47 versus 0.39, P = .043). Increased serum levels of IL-10 were associated with adverse prognostic factors and poor DLBCL outcome. The frequencies of IL-10-819T and IL-10-592A alleles were lower in patients with elevated IL-10 serum levels (0.155 versus 0.32, P = .14). As compared with patients carrying the IL-10-1082AA genotype, patients with the IL-10-1082G allele (IL-10-1082GG/GA genotypes) had higher complete remission rate (78% [confidence interval (CI), 71%-85%] versus 65% [CI, 52%-78%], P = .07), 5-year freedom from progression (FFP) (60% [CI, 52%-68%] versus 40% [CI, 27%-53%], P = .013), and overall survival (OS) (63% [CI, 55%-71%] versus 33% [CI, 20%-45%], P = .0009). Among factors of the International Prognostic Index, IL-10-1082G allele remained an independent variable, predicting longer freedom from progression (FFP) (RR [relative risk] = .76, P = .00035) and OS (RR = .78, P = .0015). These results indicate that IL-10 production contributes to the clinical course of DLBCL and that this phenomenon involves a substantial genetic component. (Blood. 2004;103:3529-3534) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma Mattias Berglund, Ulf Thunberg, Göran Roos, Richard Rosenquist, Gunilla Enblad, Gilles Salles, and Ewa Maranda Blood 2005 105: 4894-4895. [Full Text] [PDF] This article has been cited by other articles: N. Schoof, F. von Bonin, S. Zeynalova, M. Ziepert, W. Jung, M. Loeffler, M. Pfreundschuh, L. Trumper, and D. Kube Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial Ann. Onc., September 1, 2009; 20(9): 1548 - 1554. [Abstract] [Full Text] [PDF] A. J. Novak, S. L. Slager, Z. S. Fredericksen, A. H. Wang, M. M. Manske, S. Ziesmer, M. Liebow, W. R. Macon, S. R. Dillon, T. E. Witzig, et al. Genetic Variation in B-Cell-Activating Factor Is Associated with an Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma Cancer Res., May 15, 2009; 69(10): 4217 - 4224. [Abstract] [Full Text] [PDF] K. Speiran, D. P. Bailey, J. Fernando, M. Macey, B. Barnstein, M. Kolawole, D. Curley, S. S. Watowich, P. J. Murray, C. Oskeritzian, et al. Endogenous suppression of mast cell development and survival by IL-4 and IL-10 J. Leukoc. Biol., May 1, 2009; 85(5): 826 - 836. [Abstract] [Full Text] [PDF] Y. H. Park, S. K. Sohn, J. G. Kim, M.-H. Lee, H. S. Song, M. K. Kim, J. S. Jung, J.-J. Lee, H. J. Kim, and D. H. Kim Interaction between BCL2 and Interleukin-10 Gene Polymorphisms Alter Outcomes of Diffuse Large B-Cell Lymphoma following Rituximab Plus CHOP Chemotherapy Clin. Cancer Res., March 15, 2009; 15(6): 2107 - 2115. [Abstract] [Full Text] [PDF] L. A. Anderson, R. M. Pfeiffer, J. S. Rapkin, G. Gridley, L. Mellemkjaer, K. Hemminki, M. Bjorkholm, N. E. Caporaso, and O. Landgren Survival Patterns Among Lymphoma Patients With a Family History of Lymphoma J. Clin. Oncol., October 20, 2008; 26(30): 4958 - 4965. [Abstract] [Full Text] [PDF] T. M. Habermann, S. S. Wang, M. J. Maurer, L. M. Morton, C. F. Lynch, S. M. Ansell, P. Hartge, R. K. Severson, N. Rothman, S. Davis, et al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era Blood, October 1, 2008; 112(7): 2694 - 2702. [Abstract] [Full Text] [PDF] D. Kube, T.-D. Hua, F. von Bonin, N. Schoof, S. Zeynalova, M. Kloss, D. Gocht, B. Potthoff, M. Tzvetkov, J. Brockmoller, et al. Effect of Interleukin-10 Gene Polymorphisms on Clinical Outcome of Patients with Aggressive Non-Hodgkin's Lymphoma: An Exploratory Study Clin. Cancer Res., June 15, 2008; 14(12): 3777 - 3784. [Abstract] [Full Text] [PDF] J. R. Cerhan, S. M. Ansell, Z. S. Fredericksen, N. E. Kay, M. Liebow, T. G. Call, A. Dogan, J. M. Cunningham, A. H. Wang, W. Liu-Mares, et al. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma Blood, December 15, 2007; 110(13): 4455 - 4463. [Abstract] [Full Text] [PDF] E. Domingo-Domenech, Y. Benavente, E. Gonzalez-Barca, C. Montalban, J. Guma, R. Bosch, S. S. Wang, Q. Lan, D. Whitby, A. Fernandez de Sevilla, et al. Impact of interleukin-10 polymorphisms ( 1082 and 3575) on the survival of patients with lymphoid neoplasms Haematologica, November 1, 2007; 92(11): 1475 - 1481. [Abstract] [Full Text] [PDF] S Hohaus, M Giachelia, A Di Febo, M Martini, G Massini, B Vannata, F D'Alo', F Guidi, M Greco, F Pierconti, et al. Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma Ann. Onc., August 1, 2007; 18(8): 1376 - 1381. [Abstract] [Full Text] [PDF] C. F. Skibola, J. D. Curry, and A. Nieters Genetic susceptibility to lymphoma Haematologica, July 1, 2007; 92(7): 960 - 969. [Abstract] [Full Text] [PDF] J. R. Cerhan, S. Wang, M. J. Maurer, S. M. Ansell, S. M. Geyer, W. Cozen, L. M. Morton, S. Davis, R. K. Severson, N. Rothman, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival Blood, June 15, 2007; 109(12): 5439 - 5446. [Abstract] [Full Text] [PDF] W. M. Howell and M. J. Rose-Zerilli Cytokine Gene Polymorphisms, Cancer Susceptibility, and Prognosis J. Nutr., January 1, 2007; 137(1): 194S - 199S. [Abstract] [Full Text] [PDF] D. P. Bailey, M. Kashyap, L. A. Bouton, P. J. Murray, and J. J. Ryan Interleukin-10 induces apoptosis in developing mast cells and macrophages J. Leukoc. Biol., September 1, 2006; 80(3): 581 - 589. [Abstract] [Full Text] [PDF] Q. Lan, T. Zheng, N. Rothman, Y. Zhang, S. S. Wang, M. Shen, S. I. Berndt, S. H. Zahm, T. R. Holford, B. Leaderer, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma Blood, May 15, 2006; 107(10): 4101 - 4108. [Abstract] [Full Text] [PDF] I. S. Lossos and D. Morgensztern Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma J. Clin. Oncol., February 20, 2006; 24(6): 995 - 1007. [Abstract] [Full Text] [PDF] X. Ma, G. Ruan, Y. Wang, Q. Li, P. Zhu, Y.-Z. Qin, J.-L. Li, Y.-R. Liu, D. Ma, and H. Zhao Two Single-Nucleotide Polymorphisms with Linkage Disequilibrium in the Human Programmed Cell Death 5 Gene 5' Regulatory Region Affect Promoter Activity and the Susceptibility of Chronic Myelogenous Leukemia in Chinese Population Clin. Cancer Res., December 15, 2005; 11(24): 8592 - 8599. [Abstract] [Full Text] [PDF] D. Arpin, D. Perol, J.-Y. Blay, L. Falchero, L. Claude, S. Vuillermoz-Blas, I. Martel-Lafay, C. Ginestet, L. Alberti, D. Nosov, et al. Early Variations of Circulating Interleukin-6 and Interleukin-10 Levels During Thoracic Radiotherapy Are Predictive for Radiation Pneumonitis J. Clin. Oncol., December 1, 2005; 23(34): 8748 - 8756. [Abstract] [Full Text] [PDF] S. Hohaus, M. Giachelia, A. Di Febo, M. Martini, G. Massini, B. Vanata, G. Mansueto, F. Guidi, L. M. Larocca, M. T. Voso, et al. Polymorphism in Cytokine Genes as Prognostic Marker in Hodgkin's Lymphoma. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 21 - 21. [Abstract] S. Mocellin, F. M. Marincola, and H. A. Young Interleukin-10 and the immune response against cancer: a counterpoint J. Leukoc. Biol., November 1, 2005; 78(5): 1043 - 1051. [Abstract] [Full Text] [PDF] M. Berglund, U. Thunberg, G. Roos, R. Rosenquist, G. Enblad, G. Salles, and E. Maranda The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma Blood, June 15, 2005; 105(12): 4894 - 4895. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020